View Financial HealthVectorite Biomedical 配当と自社株買い配当金 基準チェック /06Vectorite Biomedical配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesReported Earnings • Apr 26Full year 2025 earnings released: EPS: NT$2.20 (vs NT$0.92 loss in FY 2024)Full year 2025 results: EPS: NT$2.20 (up from NT$0.92 loss in FY 2024). Net income: NT$96.2m (up NT$136.2m from FY 2024).お知らせ • Mar 20Vectorite Biomedical Inc., Annual General Meeting, Jun 25, 2026Vectorite Biomedical Inc., Annual General Meeting, Jun 25, 2026. Location: 6 floor no,97, sec.1 hsin t`ai 5th rd., sijhih district, new taipei city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$68m revenue, or US$2.2m). Market cap is less than US$100m (NT$619.4m market cap, or US$19.7m).New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risks Revenue is less than US$5m (NT$68m revenue, or US$2.2m). Market cap is less than US$100m (NT$755.1m market cap, or US$24.8m).New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (NT$53m revenue, or US$1.6m). Market cap is less than US$100m (NT$606.2m market cap, or US$18.4m).お知らせ • Feb 14Vectorite Biomedical Inc., Annual General Meeting, Jun 18, 2025Vectorite Biomedical Inc., Annual General Meeting, Jun 18, 2025. Location: 6 floor no,97, sec.1 hsin t`ai 5th rd., sijhih district, new taipei city TaiwanReported Earnings • Apr 28Full year 2023 earnings released: NT$0.15 loss per share (vs NT$0.60 loss in FY 2022)Full year 2023 results: NT$0.15 loss per share (improved from NT$0.60 loss in FY 2022). Revenue: NT$55.9m (up 30% from FY 2022). Net loss: NT$6.60m (loss narrowed 75% from FY 2022).お知らせ • Mar 31Vectorite Biomedical Inc., Annual General Meeting, Jun 20, 2024Vectorite Biomedical Inc., Annual General Meeting, Jun 20, 2024.New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$53m revenue, or US$1.7m). Market cap is less than US$100m (NT$763.8m market cap, or US$24.2m).決済の安定と成長配当データの取得安定した配当: 4170の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 4170の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Vectorite Biomedical 配当利回り対市場4170 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (4170)n/a市場下位25% (TW)1.4%市場トップ25% (TW)5.0%業界平均 (Biotechs)0.6%アナリスト予想 (4170) (最長3年)n/a注目すべき配当: 4170は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 4170は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 4170の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 4170が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YTW 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 09:29終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vectorite Biomedical Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 26Full year 2025 earnings released: EPS: NT$2.20 (vs NT$0.92 loss in FY 2024)Full year 2025 results: EPS: NT$2.20 (up from NT$0.92 loss in FY 2024). Net income: NT$96.2m (up NT$136.2m from FY 2024).
お知らせ • Mar 20Vectorite Biomedical Inc., Annual General Meeting, Jun 25, 2026Vectorite Biomedical Inc., Annual General Meeting, Jun 25, 2026. Location: 6 floor no,97, sec.1 hsin t`ai 5th rd., sijhih district, new taipei city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$68m revenue, or US$2.2m). Market cap is less than US$100m (NT$619.4m market cap, or US$19.7m).
New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risks Revenue is less than US$5m (NT$68m revenue, or US$2.2m). Market cap is less than US$100m (NT$755.1m market cap, or US$24.8m).
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (NT$53m revenue, or US$1.6m). Market cap is less than US$100m (NT$606.2m market cap, or US$18.4m).
お知らせ • Feb 14Vectorite Biomedical Inc., Annual General Meeting, Jun 18, 2025Vectorite Biomedical Inc., Annual General Meeting, Jun 18, 2025. Location: 6 floor no,97, sec.1 hsin t`ai 5th rd., sijhih district, new taipei city Taiwan
Reported Earnings • Apr 28Full year 2023 earnings released: NT$0.15 loss per share (vs NT$0.60 loss in FY 2022)Full year 2023 results: NT$0.15 loss per share (improved from NT$0.60 loss in FY 2022). Revenue: NT$55.9m (up 30% from FY 2022). Net loss: NT$6.60m (loss narrowed 75% from FY 2022).
お知らせ • Mar 31Vectorite Biomedical Inc., Annual General Meeting, Jun 20, 2024Vectorite Biomedical Inc., Annual General Meeting, Jun 20, 2024.
New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$53m revenue, or US$1.7m). Market cap is less than US$100m (NT$763.8m market cap, or US$24.2m).